[{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"ac72e48c-1524-449b-acbb-64797b142680","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965597","created_at":"2021-07-16T13:53:25.569Z","updated_at":"2025-02-25T16:32:32.043Z","phase":"Phase 2","brief_title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","source_id_and_acronym":"NCT04965597","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" LDH elevation","tags":["HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-07"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"cb1a79b5-e061-4b3c-834a-601d77043b7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512497","created_at":"2021-01-18T12:08:16.611Z","updated_at":"2025-02-25T14:35:44.470Z","phase":"Phase 1","brief_title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02512497","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-10-29"},{"id":"9209a8c3-cb61-49cb-9b57-ded111720987","acronym":"","url":"https://clinicaltrials.gov/study/NCT01701986","created_at":"2021-01-18T07:24:10.982Z","updated_at":"2024-07-02T16:34:37.196Z","phase":"Phase 1/2","brief_title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","source_id_and_acronym":"NCT01701986","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • clofarabine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • busulfan • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 10/25/2012","start_date":" 10/25/2012","primary_txt":" Primary completion: 06/05/2024","primary_completion_date":" 06/05/2024","study_txt":" Completion: 06/05/2024","study_completion_date":" 06/05/2024","last_update_posted":"2024-06-07"},{"id":"92222cde-38f1-4798-9e7b-0b2b4361f314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436418","created_at":"2022-06-29T15:59:10.686Z","updated_at":"2024-07-02T16:34:38.201Z","phase":"Phase 1/2","brief_title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT05436418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IGH • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 06/25/2027","primary_completion_date":" 06/25/2027","study_txt":" Completion: 07/02/2027","study_completion_date":" 07/02/2027","last_update_posted":"2024-06-05"},{"id":"2e6bf495-dfa3-4ba8-b86c-4970f2d282c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01428973","created_at":"2021-01-18T05:54:04.661Z","updated_at":"2024-07-02T16:35:04.762Z","phase":"Phase 2","brief_title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","source_id_and_acronym":"NCT01428973","lead_sponsor":"University of Liege","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-09"},{"id":"9f272c5e-b3bc-4746-bc47-098aa2fc3e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05884333","created_at":"2023-06-01T14:08:00.739Z","updated_at":"2024-07-02T16:35:06.471Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Adults With Blood Cancers","source_id_and_acronym":"NCT05884333","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 05/22/2028","primary_completion_date":" 05/22/2028","study_txt":" Completion: 05/22/2028","study_completion_date":" 05/22/2028","last_update_posted":"2024-05-02"},{"id":"422df941-e330-4ad0-9d42-14c9c566b50a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872595","created_at":"2021-05-04T11:52:44.720Z","updated_at":"2024-07-02T16:35:08.991Z","phase":"Phase 2","brief_title":"A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant","source_id_and_acronym":"NCT04872595","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • HLA-DRB1 • CD34 • CD4","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • HLA-DRB1 • CD34 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-18"},{"id":"27578ddc-f283-4d0d-bcd4-108743a5b2fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530487","created_at":"2021-01-18T21:41:28.381Z","updated_at":"2024-07-02T16:35:10.209Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","source_id_and_acronym":"NCT04530487","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 05/09/2025","primary_completion_date":" 05/09/2025","study_txt":" Completion: 05/09/2025","study_completion_date":" 05/09/2025","last_update_posted":"2024-04-11"},{"id":"db2e24eb-0bfd-4e64-8863-acd072634957","acronym":"MI-Immune","url":"https://clinicaltrials.gov/study/NCT03959241","created_at":"2021-01-18T19:29:03.481Z","updated_at":"2024-07-02T16:35:11.422Z","phase":"Phase 3","brief_title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","source_id_and_acronym":"NCT03959241 - MI-Immune","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 431","initiation":"Initiation: 06/25/2019","start_date":" 06/25/2019","primary_txt":" Primary completion: 09/19/2022","primary_completion_date":" 09/19/2022","study_txt":" Completion: 09/19/2022","study_completion_date":" 09/19/2022","last_update_posted":"2024-04-04"},{"id":"c82699ae-b7c6-4286-82ae-9872dcf1d86b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03980769","created_at":"2021-01-18T19:34:51.355Z","updated_at":"2024-07-02T16:35:20.972Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","source_id_and_acronym":"NCT03980769","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD34 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/05/2021","start_date":" 05/05/2021","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-02-05"},{"id":"7cf86a02-5513-448e-bed8-5d1eed5bad20","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162420","created_at":"2021-01-18T10:04:00.879Z","updated_at":"2024-07-02T16:35:22.078Z","phase":"","brief_title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","source_id_and_acronym":"NCT02162420","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" TERT • DKC1","pipe":"","alterations":" ","tags":["TERT • DKC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Campath (alemtuzumab) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/10/2015","start_date":" 01/10/2015","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-01-26"},{"id":"e0422d9b-926f-4a65-aa54-3c0f6660d85a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00882895","created_at":"2021-01-18T03:22:39.839Z","updated_at":"2024-07-02T16:35:22.591Z","phase":"Phase 2","brief_title":"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00882895","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • methylprednisolone sodium succinate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/05/2009","start_date":" 05/05/2009","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-01-23"},{"id":"7b20d6d4-1189-47d1-bd64-55eb31d095f7","acronym":"HAP2HCT","url":"https://clinicaltrials.gov/study/NCT03849651","created_at":"2021-01-18T19:00:01.850Z","updated_at":"2024-07-02T16:35:22.870Z","phase":"Phase 2","brief_title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT03849651 - HAP2HCT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10","pipe":" | ","alterations":" FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion","tags":["FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-19"},{"id":"35057748-3ede-43cd-9c9a-e5bbddc07de0","acronym":"GRAPPA","url":"https://clinicaltrials.gov/study/NCT05153226","created_at":"2021-12-10T23:53:28.057Z","updated_at":"2024-07-02T16:35:26.070Z","phase":"Phase 3","brief_title":"GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG","source_id_and_acronym":"NCT05153226 - GRAPPA","lead_sponsor":"DKMS gemeinnützige GmbH","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-12-15"},{"id":"bf4d31e7-3a74-43c0-9ba3-0d9c7fa6780e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03531736","created_at":"2021-01-18T17:23:50.599Z","updated_at":"2024-07-02T16:35:27.515Z","phase":"Phase 1","brief_title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","source_id_and_acronym":"NCT03531736","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 05/09/2018","start_date":" 05/09/2018","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-11-30"},{"id":"aa8537b3-cdf8-4a2f-bb71-d9e89fbfcfc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00611351","created_at":"2022-01-21T21:55:32.070Z","updated_at":"2024-07-02T16:35:32.267Z","phase":"Phase 2","brief_title":"Busulfan, Cyclophosphamide, \u0026 Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer","source_id_and_acronym":"NCT00611351","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 06/07/2005","start_date":" 06/07/2005","primary_txt":" Primary completion: 02/01/2008","primary_completion_date":" 02/01/2008","study_txt":" Completion: 09/17/2008","study_completion_date":" 09/17/2008","last_update_posted":"2023-10-20"},{"id":"8141f3b3-b073-4d91-bde0-869625884d73","acronym":"","url":"https://clinicaltrials.gov/study/NCT03480360","created_at":"2021-05-03T18:54:00.006Z","updated_at":"2024-07-02T16:35:32.843Z","phase":"Phase 3","brief_title":"Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression","source_id_and_acronym":"NCT03480360","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/28/2018","start_date":" 03/28/2018","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 09/13/2025","study_completion_date":" 09/13/2025","last_update_posted":"2023-10-18"},{"id":"76db4819-1806-4f6d-8363-46b52b7992fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03096782","created_at":"2021-01-18T15:15:32.124Z","updated_at":"2024-07-02T16:35:33.856Z","phase":"Phase 2","brief_title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","source_id_and_acronym":"NCT03096782","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 09/20/2022","primary_completion_date":" 09/20/2022","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2023-10-11"},{"id":"fe47d81d-281e-4a03-a25c-2119fd0bd270","acronym":"","url":"https://clinicaltrials.gov/study/NCT03608059","created_at":"2021-01-18T17:44:13.474Z","updated_at":"2024-07-02T16:35:34.652Z","phase":"Phase 4","brief_title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","source_id_and_acronym":"NCT03608059","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 418","initiation":"Initiation: 07/28/2018","start_date":" 07/28/2018","primary_txt":" Primary completion: 08/23/2023","primary_completion_date":" 08/23/2023","study_txt":" Completion: 08/23/2023","study_completion_date":" 08/23/2023","last_update_posted":"2023-10-05"},{"id":"4ca8b414-9077-4b6b-b132-a2fdb98fe759","acronym":"","url":"https://clinicaltrials.gov/study/NCT04521946","created_at":"2021-01-18T21:39:42.879Z","updated_at":"2024-07-02T16:35:34.835Z","phase":"Phase 1","brief_title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","source_id_and_acronym":"NCT04521946","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C • KIR2DS2","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C • KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • melphalan • fludarabine IV • thiotepa"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 12/20/2022","primary_completion_date":" 12/20/2022","study_txt":" Completion: 12/20/2022","study_completion_date":" 12/20/2022","last_update_posted":"2023-10-04"},{"id":"62e6dd26-f72c-4fcc-8764-7edf4040bf20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04098393","created_at":"2021-01-18T20:03:07.893Z","updated_at":"2024-07-02T16:35:34.812Z","phase":"Phase 1","brief_title":"Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation","source_id_and_acronym":"NCT04098393","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TP53 • ABL1 • BCR","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/18/2019","start_date":" 09/18/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-10-04"},{"id":"a4c2ebb0-b6de-4797-9fa4-06a37d8a44b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02122081","created_at":"2021-01-18T09:49:45.733Z","updated_at":"2024-07-02T16:35:36.447Z","phase":"Phase 1","brief_title":"Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","source_id_and_acronym":"NCT02122081","lead_sponsor":"Sumithira Vasu","biomarkers":" CD8 • HLA-DRB1 • CD4 • NCAM1 • HLA-B • HLA-C","pipe":" | ","alterations":" NCAM1 positive","tags":["CD8 • HLA-DRB1 • CD4 • NCAM1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 07/27/2015","start_date":" 07/27/2015","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2023-09-21"}]